Evidence map›Paper›PMID 29713497›Full record

ArticleSignal transduction and targeted therapy

Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting

Kentaro Miyake, Tasuku Kiyuna, Masuyo Miyake, Kei Kawaguchi, Sang Nam Yoon, Zhiying Zhang, Kentaro Igarashi, Sahar Razmjooei, Sintawat Wangsiricharoen, Takashi Murakami and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
  2. Review
  3. Article
  4. The Combination of Tumor-targetingIn vivo (Athens, Greece)
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Kentaro Miyake1AntiCancer, Inc., San Diego, CA USA.ORCID 0000-0002-4680-4317
Tasuku Kiyuna1AntiCancer, Inc., San Diego, CA USA.
Masuyo Miyake1AntiCancer, Inc., San Diego, CA USA.
Kei Kawaguchi1AntiCancer, Inc., San Diego, CA USA.
Sang Nam Yoon1AntiCancer, Inc., San Diego, CA USA.
Zhiying Zhang1AntiCancer, Inc., San Diego, CA USA.
Kentaro Igarashi1AntiCancer, Inc., San Diego, CA USA.
Sahar Razmjooei1AntiCancer, Inc., San Diego, CA USA.
Sintawat Wangsiricharoen1AntiCancer, Inc., San Diego, CA USA.
Takashi Murakami3Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yunfeng Li4Department of Pathology, University of California, Los Angeles, CA USA.
Scott D Nelson4Department of Pathology, University of California, Los Angeles, CA USA.
Tara A Russell5Division of Surgical Oncology, University of California, Los Angeles, CA USA.
Arun S Singh6Division of Hematology-Oncology, University of California, Los Angeles, CA USA.
Yukihiko Hiroshima3Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Masashi Momiyama3Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Ryusei Matsuyama3Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Takashi Chishima3Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Shree Ram Singh7Basic Research Laboratory, National Cancer Institute, Frederick, MD USA.ORCID 0000-0001-6545-583X
Itaru Endo3Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Fritz C Eilber5Division of Surgical Oncology, University of California, Los Angeles, CA USA.
Robert M Hoffman1AntiCancer, Inc., San Diego, CA USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer of unknown primary (CUP) is a recalcitrant disease with poor prognosis because it lacks standard first-line therapy. CUP consists of diverse malignancy groups, making personalized precision therapy essential. The present study aimed to identify an effective therapy for a CUP patient using a patient-derived orthotopic xenograft (PDOX) model. This paper reports the usefulness of the PDOX model to precisely identify effective and ineffective chemotherapy and to compare the efficacy of

Identifiers

PMID29713497
PMCPMC5923205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.